- Home
- WVE vs MLTX Comparison
WVE vs MLTX Comparison
Compare WVE & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- MLTX
- Stock Information
- Founded
- WVE 2012
- MLTX 2021
- Country
- WVE Singapore
- MLTX Switzerland
- Employees
- WVE N/A
- MLTX N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- WVE Health Care
- MLTX Health Care
- Exchange
- WVE Nasdaq
- MLTX Nasdaq
- Market Cap
- WVE 915.6M
- MLTX 904.7M
- IPO Year
- WVE 2015
- MLTX N/A
- Fundamental
- Price
- WVE $7.35
- MLTX $12.88
- Analyst Decision
- WVE Strong Buy
- MLTX Buy
- Analyst Count
- WVE 14
- MLTX 9
- Target Price
- WVE $20.50
- MLTX $36.33
- AVG Volume (30 Days)
- WVE 3.6M
- MLTX 2.3M
- Earning Date
- WVE 11-10-2025
- MLTX 11-05-2025
- Dividend Yield
- WVE N/A
- MLTX N/A
- EPS Growth
- WVE N/A
- MLTX N/A
- EPS
- WVE N/A
- MLTX N/A
- Revenue
- WVE $109,230,000.00
- MLTX N/A
- Revenue This Year
- WVE N/A
- MLTX N/A
- Revenue Next Year
- WVE $6.24
- MLTX N/A
- P/E Ratio
- WVE N/A
- MLTX N/A
- Revenue Growth
- WVE 103.75
- MLTX N/A
- 52 Week Low
- WVE $5.28
- MLTX $5.95
- 52 Week High
- WVE $16.38
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- WVE 49.41
- MLTX 45.07
- Support Level
- WVE $6.60
- MLTX $12.43
- Resistance Level
- WVE $7.27
- MLTX $13.99
- Average True Range (ATR)
- WVE 0.53
- MLTX 0.75
- MACD
- WVE -0.04
- MLTX 0.89
- Stochastic Oscillator
- WVE 51.78
- MLTX 72.05
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.